Table 2.

Survival for GMS according to low- and high-risk disease and location of cancer in the validation cohort (n = 862).

GroupGMS category		Disease-free survival				Relapse-free survival
	N	5-year DFS (%; SE)	Events (n = 541)	HR (95% CI)	P	5-year RFS (%; SE)	Events (n = 271)	HR (95% CI)	P
Full cohort				Trend	0.003			Trend	<0.001
0	300	71 (3)	168	1.0 (reference)		83 (2)	61	1.0 (reference)
1	424	58 (2)	281	1.30 (1.08–1.58)	0.007	70 (2)	141	1.82 (1.35-2.46)	<0.001
2	138	46 (4)	92	1.50 (1.16–1.93)	0.002	51 (4)	69	3.09 (2.19-4.36)	<0.001
TNM I–II (low risk)				Trend	0.89			Trend	<0.001
0	201	73 (3)	113	1.0 (reference)		88 (2)	29	1.0 (reference)
1	244	70 (3)	148	1.06 (0.83–1.35)	0.65	84 (2)	49	1.42 (0.90–2.25)	0.13
2	54	57 (7)	29	1.06 (0.70–1.59)	0.79	63 (7)	21	3.24 (1.85–5.68)	<0.001
TNM II–III (high risk)				Trend	0.003			Trend	0.001
0	99	66 (5)	55	1.0 (reference)		72 (5)	32	1.0 (reference)
1	180	43 (4)	133	1.67 (1.22–2.29)	0.001	51 (4)	92	1.95 (1.30–2.92)	0.001
2	84	38 (5)	63	1.72 (1.19–2.47)	0.003	43 (6)	48	2.18 (1.39–3.41)	0.001
Colon cancer				Trend	0.004			Trend	<0.001
0	206	72 (3)	113	1.0 (reference)		84 (3)	41	1.0 (reference)
1	345	58 (3)	233	1.38 (1.10–1.73)	0.005	69 (3)	115	1.88 (1.32–2.68)	0.001
2	99	45 (5)	67	1.57 (1.16–2.12)	0.004	51 (5)	49	3.15 (2.08–4.77)	<0.001
Rectal cancer				Trend	0.46			Trend	0.003
0	94	68 (5)	55	1.0 (reference)		80 (4)	20	1.0 (reference)
1	79	62 (5)	48	1.07 (0.73–1.58)	0.72	72 (5)	26	1.66 (0.92–2.97)	0.09
2	39	46 (8)	25	1.35 (0.84–2.17)	0.21	51 (8)	20	2.95 (1.58–5.48)	0.001

DFS disease-free survival, RFS relapse-free survival.

Emboldened values indicates p value < 0.05